DARPP-32 (phospho-T34) polyclonal, anti-human, mouse, rat
€328.00
In stock
SKU
BS4782
Background:
Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson’s disease and drug abuse. DARPP-32 (for dopamine and adenosine 3’,5’-monophosphate-regulated phosphoprotein of 32 kDa) is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on threonine occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32. Neurotransmitters other than dopamine may also be able to stimulate the phosphorylation or dephosphorylation of DARPP-32. Phosphorylated DARPP-32 is a potent inhibitor of PP-1.
Alternative Name:
Protein phosphatase 1 regulatory subunit 1B, DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein, PPP1R1B, DARPP32
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: p-DARPP-32 (T34) polyclonal antibody detects endogenous levels of DARPP-32 protein only when phosphorylated at Thr34.
Immunogen:
Synthetic phosphopeptide derived from human DARPP-32 around the phosphorylation site of Threonine 34.
MW: ~ 32 kDa
Swis Prot.: Q9UD71
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson’s disease and drug abuse. DARPP-32 (for dopamine and adenosine 3’,5’-monophosphate-regulated phosphoprotein of 32 kDa) is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on threonine occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32. Neurotransmitters other than dopamine may also be able to stimulate the phosphorylation or dephosphorylation of DARPP-32. Phosphorylated DARPP-32 is a potent inhibitor of PP-1.
Alternative Name:
Protein phosphatase 1 regulatory subunit 1B, DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein, PPP1R1B, DARPP32
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: p-DARPP-32 (T34) polyclonal antibody detects endogenous levels of DARPP-32 protein only when phosphorylated at Thr34.
Immunogen:
Synthetic phosphopeptide derived from human DARPP-32 around the phosphorylation site of Threonine 34.
MW: ~ 32 kDa
Swis Prot.: Q9UD71
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review